A Look At STERIS (STE) Valuation After Recent Share Price Weakness

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Recent share performance and business scale

STERIS (STE) has drawn investor attention after a period in which the stock declined about 6% over the past month and roughly 14% over the past 3 months, prompting closer review of its fundamentals.

The company reports annual revenue of US$5.94b and net income of US$782.3m, with operations spanning Healthcare, Applied Sterilization Technologies and Life Sciences, and a market value of about US$20.68b.

See our latest analysis for STERIS.

At a share price of US$211.10, STERIS has seen its short term momentum fade, with the share price down 6.12% over the past month and total shareholder return of 16.78% over five years indicating steadier progress over a longer horizon.

If you are reassessing healthcare exposure after STERIS's recent share price moves, it can be useful to compare this trend with other medical technology plays by scanning 33 healthcare AI stocks

With STERIS trading at US$211.10 and screens flagging an estimated intrinsic discount of about 7%, the key question for you is simple: is there meaningful upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 24.4% Undervalued

Against the last close of $211.10, the most followed narrative pegs STERIS's fair value at $279.29, framing the current share price as a discount that hinges on specific growth and margin assumptions.

Continued expansion of STERIS's consumables and services segments, with high recurring revenue and margin visibility, positions the company to benefit from increasing healthcare expenditures and adoption of best practice infection control standards, supporting both revenue and margin expansion.

Read the complete narrative.

Want to see what is baked into that valuation gap? The narrative leans heavily on steady revenue compounding, rising profitability, and a richer future earnings multiple. The exact mix of growth, margins, and discount rate assumptions is where the story really gets interesting.

Result: Fair Value of $279.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this relies on key assumptions holding up, and tariff pressures or tougher healthcare reimbursement could easily challenge both margin expectations and capital spending.

Find out about the key risks to this STERIS narrative.

Another View: What The P/E Ratio Is Saying

That narrative backed fair value of $279.29 paints STERIS as 24.4% undervalued, but the P/E ratio tells a tighter story. At 26.5x earnings, the stock trades richer than the US Medical Equipment industry at 24.1x and above its own fair ratio of 23.8x. This points to less margin for error if growth or margins disappoint.

Story Continues

For you, that gap means sentiment is already paying a premium for the business, so any wobble in earnings or cash flow could hit the share price harder than a stock priced closer to the fair ratio. The question is simple: are you comfortable paying up for this profile today, or do you prefer to wait for a cleaner entry point?

See what the numbers say about this price — find out in our valuation breakdown.NYSE:STE P/E Ratio as at May 2026

Next Steps

Given the mixed signals on value and expectations, it can be helpful to move quickly, review the underlying data yourself, and decide where you stand. To see what investors are optimistic about, take a closer look at the company's 4 key rewards

Looking for more investment ideas?

If STERIS is on your radar, do not stop here. Use the Simply Wall St screener to compare other opportunities and keep your watchlist working harder for you.

Shift your focus toward quality opportunities trading below their estimated value by running a quick scan using the 47 high quality undervalued stocks. Strengthen your income stream potential by reviewing companies that meet the yield threshold in the 14 dividend fortresses. Zero in on resilient businesses that aim to limit downside risk through the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include STE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments